These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 19423276)

  • 1. [Anthracycline-induced cardiomyopathy].
    Roul G; Cohen C; Lieber A
    Presse Med; 2009 Jun; 38(6):987-94. PubMed ID: 19423276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy.
    Kobza C
    Clin J Oncol Nurs; 2021 Jun; 25(3):259-266. PubMed ID: 34019025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
    Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
    J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.
    Gujral DM; Lloyd G; Bhattacharyya S
    Breast; 2018 Feb; 37():64-71. PubMed ID: 29101824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic prevention of anthracycline-induced cardiomyopathy.
    Maradia K; Guglin M
    Cardiol Rev; 2009; 17(5):243-52. PubMed ID: 19690476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardioprotection in women with neoplastic disease].
    Cardinale D; Colombo A; Bacchiani G
    G Ital Cardiol (Rome); 2012 Jun; 13(6):461-8. PubMed ID: 22622126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of afterload reduction in the prevention of late anthracycline cardiomyopathy.
    Silber JH
    Pediatr Blood Cancer; 2005 Jun; 44(7):607-13. PubMed ID: 15795884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthracycline-induced cardiomyopathy.
    Simmons A; Vacek JL; Meyers D
    Postgrad Med; 2008 Nov; 120(4):67-72. PubMed ID: 19020367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
    Janbabai G; Nabati M; Faghihinia M; Azizi S; Borhani S; Yazdani J
    Cardiovasc Toxicol; 2017 Apr; 17(2):130-139. PubMed ID: 27003392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy.
    Pinarli FG; Oğuz A; Tunaoğlu FS; Karadeniz C; Gökçora N; Elbeg S
    Pediatr Blood Cancer; 2005 Apr; 44(4):370-7. PubMed ID: 15602715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac toxicity after anthracycline chemotherapy in childhood.
    Iarussi D; Indolfi P; Galderisi M; Bossone E
    Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dilated cardiomyopathy post-chemotherapy].
    Sbrana F; Greco P; Rovai D
    Recenti Prog Med; 2009 Mar; 100(3):132-6. PubMed ID: 19475840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional practice norms for the care of childhood cancer survivors at risk for cardiomyopathy: A Delphi study.
    Kenney LB; Ames B; Margossian R; Moss K; Michaud AL; Williams DN; Nohria A
    Pediatr Blood Cancer; 2019 Sep; 66(9):e27868. PubMed ID: 31148382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Severe heart failure in consequence of late anthracycline-induced cardiotoxicity--case report].
    Urbanová D; Bubanská E; Hrebík M; Mladosievicová B
    Klin Onkol; 2009; 22(1):34-7. PubMed ID: 19534438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthracycline-induced cardiomyopathy.
    Fisher NG; Marshall AJ
    Postgrad Med J; 1999 May; 75(883):265-8. PubMed ID: 10533628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies.
    Cadeddu C; Mercurio V; Spallarossa P; Nodari S; Triggiani M; Monte I; Piras R; Madonna R; Pagliaro P; Tocchetti CG; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e64-e75. PubMed ID: 27755244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
    Spallarossa P; Maurea N; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e84-e92. PubMed ID: 27755246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.